This presentation is an introduction to Oncology Data Science at AstraZeneca and the important work being done to impact decision making to advance AstraZeneca’s oncology drug portfolio. Steven Criscione will also share a research vignette on our study of the EGFR inhibitor osimertinib drug tolerant persister cells. In the study, the team performed dynamic multiomics of drug response to EGFR inhibitor osimertinib and identified changes to the transcriptome and epigenome in osimertinib drug tolerant cells. They integrated these studies with drug combination screens and identified drug combinations that can eliminate osimertinib drug tolerant cells. They also validated several of the drug combination vulnerabilities including a vulnerability to Hippo pathway modulation.
Presenter
